Sugi Predict

Sugi Predict / Compounds / SCHEMBL2748587

SCHEMBL2748587

SCHEMBL2748587

Cc1cccc2nc(S)sc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 1/20 0.35
▸ NPC1 O15118 4/20 0.35
▸ RAB9A P51151 4/20 0.35
▸ SMN1; SMN2 Q16637 3/20 0.35
▸ LMNA P02545 1/20 0.35
▸ NFKB1 P19838 1/20 0.35
▸ NFKB2 Q00653 1/20 0.35
▸ RELA Q04206 1/20 0.35
▸ NQO2 P16083 1/20 0.34
▸ MEN1 O00255 2/20 0.34
▸ KMT2A Q03164 2/20 0.34
▸ HCRTR1 O43613 1/20 0.34
▸ PARP15 Q460N3 1/20 0.34
▸ PARP10 Q53GL7 1/20 0.34
▸ TNKS2 Q9H2K2 1/20 0.34
▸ PARP2 Q9UGN5 1/20 0.34
▸ PARP1 P09874 2/20 0.33
▸ ELANE P08246 1/20 0.33
▸ PSMB8 P28062 1/20 0.33
▸ HSP90AA1 P07900 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7958840 0.79 RAB9A (0.49) ALDH1A1NPC1RAB9ASMN1; SMN2LMNA
SCHEMBL31063715 0.79 RAB9A (0.49) ALDH1A1NPC1RAB9ASMN1; SMN2LMNA
SCHEMBL9305472 0.78 APP (0.46) ALDH1A1NPC1RAB9ASMN1; SMN2LMNA
SCHEMBL9305633 0.77 CA2 (0.38) ALDH1A1PSMB8CASRAPP
SCHEMBL2748734 0.77 NQO2 (0.46) ALDH1A1NPC1RAB9ASMN1; SMN2LMNA
SCHEMBL2748327 0.76 PSMB8 (0.36) ALDH1A1NPC1RAB9ASMN1; SMN2LMNA
SCHEMBL663501 0.76 BACE1 (0.36) PSMB8HSP90AA1HSP90AB1
SCHEMBL2749435 0.76 PSMB8 (0.56) ALDH1A1SMN1; SMN2LMNAMEN1KMT2A
SCHEMBL289210 0.76 SMN1; SMN2 (0.56) ALDH1A1NPC1RAB9ASMN1; SMN2HSP90AA1
SCHEMBL30003135 0.76 SMN1; SMN2 (0.56) ALDH1A1NPC1RAB9ASMN1; SMN2HSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3247751-B1 ANTICORROSION COMPOSITION AND PROCESS FOR PREPARING AN ATICORROSION LAYER ON A SURFACE OF A SUBSTRATE USING SAID COMPOSITION SOCOMORE (FR) 2022-10-19 — — EP claimed
EP-3247751-A1 CORROSION-RESISTANT COMPOSITION AND METHOD FOR PREPARING A CORROSION-RESISTANT LAYER ON A SURFACE OF A SUBSTRATE USING SAID COMPOSITION Socomore (FR) 2017-11-29 — — EP claimed
WO-2016116605-A1 CORROSION-RESISTANT COMPOSITION AND METHOD FOR PREPARING A CORROSION-RESISTANT LAYER ON A SURFACE OF A SUBSTRATE USING SAID COMPOSITION SOCOMORE (FR) 2016-07-28 — — WO claimed
EP-3247751-B1 ANTICORROSION COMPOSITION AND PROCESS FOR PREPARING AN ATICORROSION LAYER ON A SURFACE OF A SUBSTRATE USING SAID COMPOSITION SOCOMORE (FR) 2022-10-19 — — EP disclosed
EP-2773207-B1 AMINOPYRIMIDINONES AS INTERLEUKIN RECEPTOR-ASSOCIATED KINASE INHIBITORS MERCK SHARP & DOHME (US) 2018-03-07 — — EP disclosed
EP-2773207-B1 AMINOPYRIMIDINONES AS INTERLEUKIN RECEPTOR-ASSOCIATED KINASE INHIBITORS MERCK SHARP & DOHME (US) 2018-03-07 — — EP disclosed
EP-3247751-A1 CORROSION-RESISTANT COMPOSITION AND METHOD FOR PREPARING A CORROSION-RESISTANT LAYER ON A SURFACE OF A SUBSTRATE USING SAID COMPOSITION Socomore (FR) 2017-11-29 — — EP disclosed
WO-2016116605-A1 CORROSION-RESISTANT COMPOSITION AND METHOD FOR PREPARING A CORROSION-RESISTANT LAYER ON A SURFACE OF A SUBSTRATE USING SAID COMPOSITION SOCOMORE (FR) 2016-07-28 — — WO disclosed
US-9221809-B2 Aminopyrimidinones as interleukin receptor-associated kinase inhibitors MERCK SHARP & DOHME CORP. (US) 2015-12-29 — — US disclosed
US-9221809-B2 Aminopyrimidinones as interleukin receptor-associated kinase inhibitors MERCK SHARP & DOHME CORP. (US) 2015-12-29 — — US disclosed
US-9221809-B2 Aminopyrimidinones as interleukin receptor-associated kinase inhibitors MERCK SHARP & DOHME CORP. (US) 2015-12-29 — — US disclosed
WO-2007075572-A2 ORALLY ACTIVE PURINE-BASED INHIBITORS OF HEAT SHOCK PROTEIN 90 CONFORMA THERAPEUTICS CORPORATION (US) 2007-07-05 — — WO disclosed
WO-2007075572-A2 ORALLY ACTIVE PURINE-BASED INHIBITORS OF HEAT SHOCK PROTEIN 90 CONFORMA THERAPEUTICS CORPORATION (US) 2007-07-05 — — WO disclosed
US-20070129334-A1 Orally Active Purine-Based Inhibitors of Heat Shock Protein 90 CONFORMA THERAPEUTICS CORPORATION (US) 2007-06-07 — — US disclosed
US-20070129334-A1 Orally Active Purine-Based Inhibitors of Heat Shock Protein 90 CONFORMA THERAPEUTICS CORPORATION (US) 2007-06-07 — — US disclosed
US-20070129334-A1 Orally Active Purine-Based Inhibitors of Heat Shock Protein 90 CONFORMA THERAPEUTICS CORPORATION (US) 2007-06-07 — — US disclosed
US-4343660-A PETROLEUM SULFONATE AND COMPLEXING AGENT, FOR COPPER CABLES PETROLITE CORPORATION (US) 1982-08-10 — — US disclosed
US-4138346-A ETHOXYLATED PHOSPHATE ESTER WITH A MERCAPTOTHIAZOLE, A DITHIOBIS-THIAZOLE, A SULFIDE, A DISULFIDE OR A SULFONE BASF WYANDOTTE CORPORATION (US) 1979-02-06 — — US disclosed
US-3967951-A 1,3-DIMETHYL-1-(2-5-(TERT-BUTYL OR ISOPROPYL)BENZOTHIAZOLYL)UREA NIPPON SODA COMPANY LIMITED (JA) 1976-07-06 — — US disclosed
US-3933658-A PHOSPHATE ESTER AND SULFUR COMPOUND GAF CORPORATION (US) 1976-01-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129334-A1 Orally Active Purine-Based Inhibitors of Heat Shock Protein 90 HSP90AB1, HSP90AA1, HSP90AB2P ALDH1A1 2219/4885NPC1 1532/4885RAB9A 2657/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.